Customize your JAMA Network experience by selecting one or more topics from the list below.
Copyright 2017 American Medical Association. All Rights Reserved.
In the Original Investigation entitled “Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial”1 published in the December 20, 2016, issue of JAMA, data were omitted. The Design, Setting, and Participants section of the Abstract should have reported that “45 participants were randomized to receive pritelivir.” In the Results section of the Abstract, the relative risk during valacyclovir treatment should have been reported as “0.42.” In Table 1, the upper bound of the confidence intervals in the “HSV DNA log10 copies/mL” subsection should have been reported as “0.5,” “−0.1,” and “1.0,” respectively. The second and third row stubs in the “Clinical End Points” section should have read “Recurrence or incidence rate” and “Days with pain,” respectively. This article has been corrected online.
Omission of Data. JAMA. 2017;317(6):648. doi:10.1001/jama.2017.0040
Create a personal account or sign in to: